DeepScribe vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco ambient AI scribe using smartphone to listen to patient visits; generates structured EHR notes within minutes, customizable to each physician's documentation style.
About
DeepScribe is a San Francisco-based ambient AI medical scribe company that uses machine learning to listen to physician-patient conversations and automatically generate complete, structured clinical documentation without physician dictation or manual entry. The platform runs on a smartphone placed in the exam room, processes the conversation to identify medically relevant information, and presents a complete draft note in the EHR within minutes of the visit ending. DeepScribe differentiates through its customization capabilities — physicians can train the AI to match their personal documentation style, preferred note templates, and specialty-specific terminology, making the output immediately publishable with minimal editing. The company serves primary care, specialty, and urgent care physicians as well as telehealth providers. Founded in 2017, DeepScribe raised over $30M from investors including Kaiser Permanente Ventures, Greycroft, and SignalFire. The company has demonstrated significant time savings for clinicians and reductions in EHR-related stress. It competes with Suki AI, Nuance DAX, and Freed AI in the ambient medical scribe market.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.